Robot-assisted surgery for early uterine corpus cancer: assessing the learning curve

Minimally invasive surgery (MIS) is performed for various human cancers, among which robot-assisted surgery is widely used in the United States, Europe, and other countries. Presently, the total number of robot-assisted surgeries in gynecology exceeds that in urology and any other clinical department. Our group began using robot-assisted surgery for early-stage uterine corpus cancer as from November 2017 and has already performed 40 robot-assisted operations. For this study, we examined the cases of 35 patients, excluding 3 in whom lymphadenectomy was not performed and 2 who underwent additional vaginal wall plasty. Compared with the first 20 cases, the latter 15 had reduced bleeding and shorter operation times. No serious complications were observed in the whole cohort, but infections, including urinary tract infections and peritonitis, were common among the first 20 patients. Although robot-assisted surgery is considered more advantageous for obese patients than laparoscopic and open surgery, we found no significant differences in bleeding, surgical time, or the number of resected lymph nodes between obese patients (Body Mass Index (BMI) >= 30) and other patients in this present study. Robot-assisted surgery is expected to be more widely used, and further technical improvements are needed.